Immuno-Oncology (IO)

The fourth pillar of cancer therapy?1

Interest in immuno-oncology (IO) has been longstanding, dating back to the 1980s. However, it has not been until now—the modern era of IO therapy—that we have seen rapid change in the field, leading to the development of antibodies that affect the antitumour immune response. In light of these recent developments, IO therapy is increasingly being recognized as the fourth pillar of cancer therapy, alongside surgery, radiotherapy and cancer therapy.1

* Not an exhaustive list of cancer types or recommendations. Please refer to the respective NCCN Guidelines for more information about the appropriate patients, cancers, and cancer stages.

References: 1. Butterfield, LH et al. Cancer Immunotherapy Principles and Practice. 2017. (Springer Publishing Company, Incorporated). 2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. 2020. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed March 2021.